Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Domain Therapeutics

News headline image
Domain Therapeutics Strengthens Its Intellectual Property for Its Series of Treg Depleting anti-CCR8 Antibodies, Including Best-in-class Candidate DT-7012
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics Appoints Sean A. MacDonald as Chief Executive Officer
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics to Participate at Premier Investor and Healthcare Conferences
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics Further Strengthens Leadership Team With Appointment of Sean A. MacDonald as Chief Business Officer
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics Awarded Hospital-University Research in Health (RHU) SPRINT Consortium Grant to Progress Its Proprietary CCR8 Antibody Candidate to the Clinic
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics Receives a Single Digit Multimillion Development Milestone Payment from Merck for M1069 Clinical Development in Immuno-Oncology
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer
From Domain Therapeutics
Via Business Wire
News headline image
Domain Therapeutics Raises $42m Series A Financing
From Domain Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.